Cies. JAMA Intern Med. 2014;174:1558?5. Holley JL. Preventive medical …

Cies. JAMA Intern Med. 2014;174:1558?5. Holley JL. Preventive medical screening is not appropriate for many chronic dialysis patients. Semin Dial. 2000;13:369?1.28. LeBrun CJ, Diehl LF, Abbott KC, Welch PG, Yuan CM. Life expectancy benefits of cancer screening in the end-stage renal disease population. Am J Kidney Dis. 2000;35:237?3. 29. Nakai S, Hanafusa N, Masakane I, Taniguchi M, Hamano T, Shoji T, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2012). Ther Apher Dial. 2014;18:535?02. 30. Goodkin DA, Bragg-Gresham JL, Koenig KG, Staurosporine Wolfe RA, Akiba T, Andreucci VE, et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol. 2003;14:3270?. 31. Holley JL. Screening, diagnosis, and treatment of cancer in long-term dialysis patients. Clin J Am Soc Nephrol. 2007;2:604?0. 32. Odagiri E, Jibiki K, Takeda M, Sugimura H, Iwachika C, Abe Y, et al. Effect of hemodialysis on PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/15501003 the concentration of the seven tumor markers carcinoembryonic antigen, alpha-fetoprotein, squamous cell carcinomarelated antigen, neuron-specific enolase, CA 125, CA 19-9 and CA 15-3 in uremic patients. Am J Nephrol. 1991;11:363?. 33. Kashiwabara K, Nakamura H, Yagyu H, Kishi K, Matsuoka T, Esaki T. Changes in squamous cell carcinoma-related antigen levels before and after hemodialysis in relation to the model of dialyzer employed. Intern Med. 2000;39:291?. 34. Christensson A, Bj k T, Nilsson O, Dahl U, Matikainen MT, Cockett AT, et al. Serum prostate specific antigen complexed to alpha 1antichymotrypsin as an indicator of prostate cancer. J Urol. 1993;150:100?. 35. Bruun L, Bj k T, Lilja H, Becker C, Gustafsson O, Christensson A. Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment. Nephrol Dial Transplant. 2003;18:598?03. 36. Zeimet AG, Marth C, Offner FA, Obrist P, Uhl-Steidl M, Feichtinger H, et al. Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol Oncol. 1996;62:384?. 37. Sevinc A, Buyukberber S, Sari R, Kiroglu Y, Turk HM, Ates M. Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids. Gynecol Oncol. 2000;77:254?. 38. Bastani B, Chu N. Serum CA-125 level in end-stage renal disease patients maintained on chronic peritoneal dialysis or hemodialysis: the effect of continuous presence of peritoneal fluid, peritonitis, and peritoneal catheter implantation. Am J Nephrol. 1995;15:468?2. 39. Xiaofang Y, Yue Z, Xialian X, Zhibin Y. Serum tumour markers in patients with chronic kidney disease. Scand J Clin Lab Invest. 2007;67:661?. 40. Filella X, Cases A, Molina R, Jo J, Bedini JL, Revert L, et al. Tumor markers in patients with chronic renal failure. Int J Biol Markers. 1990;5:85?. 41. Arik N, Adam B, Akpolat T, Hail K, Tabak S. Serum tumour markers in renal failure. Int Urol Nephrol. 1996;28:601?. 42. Tzitzikos G, Saridi M, Filippopoulou T, Makri A, Goulioti A, Stavropoulos T, et al. Measurement of tumor markers in chronic hemodialysis patients. Saudi J Kidney Dis Transpl. 2010;21:50?. 43. Arican A, Ozdemir N, Sezer S, Erten Y, G G, Turan M, et al. Tumor markers in hemodialysis patients. Transplant Proc. 1999;31:3367?. 44. Ajam M, Ramanujam LS, Gandhi VC, Leehey DJ, Ing TS, Schnell TG, et al. Colon-cancer screening in dialysis patients. Artif Org.